SAREPTA THERAPEUTICS, INC. Restructuring and Related Cost, Number of Positions Eliminated
SAREPTA THERAPEUTICS, INC. (SRPT) had Restructuring and Related Cost, Number of Positions Eliminated of 500 Workforce as of 2025-07-16, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. restructuring and related cost, number of positions eliminated for fiscal 2011 was 35.00 Position.
Position
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|---|
| 2012-11-30 | 21.00 Position 10-K · filed 2015-02-26 | |
| 2011-12-31 | 35.00 Position 10-K · filed 2015-02-26 |
Workforce
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2025-07-16 | 500.00 Workforce 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |